Last reviewed · How we verify
NCT03428555: CARIBOU
Integrated Care Pathway for Youth Depression
NA trial testing Integrated Care Pathway in ICP1 in 60 participants. Status unknown.
29 August 2019
Quick facts
| Lead sponsor | Centre for Addiction and Mental Health |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 29 March 2018 |
| Primary completion | 29 August 2019 |
| Estimated completion | 21 February 2020 |
| Sites | 2 locations across Canada |
Drugs / interventions tested
- Integrated Care Pathway
- Treatment As Usual
Conditions studied
- ICP1 — all drugs for ICP1 →
- Depression — all drugs for Depression →
- Adolescent Behavior — all drugs for Adolescent Behavior →
Sponsor
Centre for Addiction and Mental Health — full company profile →
Who can join
Adults 14 to 18, any sex, with ICP1 or Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Major Depressive Disorder in adolescence is prevalent and debilitating. Our group aims to improve treatment response through the use of an Integrated Care Pathway (ICP) based on a high quality Clinical Practice Guideline and measurement-based care (MBC; where periodic symptom scale scores are used to make treatment decisions). We propose a controlled clinical trial comparing ICP to treatment-as-usual (TAU) across two sites.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
CARIBOU-1: A pilot controlled trial of an Integrated Care Pathway for the treatment of depression in adolescents.
Courtney DB, Cheung A, Henderson J, Bennett K, et al · · 2022 · cited 7× · PMID 37431464 · DOI 10.1002/jcv2.12083 -
Effectiveness of an Integrated Care Pathway for Adolescents with Depression: A Pilot Clinical Trial Protocol.
Courtney DB, Cheung A, Henderson J, Bennett K, et al · · 2019 · cited 6× · PMID 31798650
Verify or expand the search:
- PubMed search for NCT03428555
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Centre for Addiction and Mental Health trials
Trials by the same sponsor.
- NCT07211438 — Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression · Phase 2 · not yet recruiting
- NCT07146633 — Efficacy of an EMDR App for PTSD and SUD · NA · recruiting
- NCT07228923 — Development and Evaluation of a Theory and Evidence-based Intervention to Reduce Hazardous Alcohol Consumption Among Tre · NA · not yet recruiting
- NCT07105449 — THC Titration of High-Potency Cannabis Concentrates · NA · not yet recruiting
- NCT06928935 — Digital Dialectical Behavioural Therapy (d-DBT) for Youth at Clinical High Risk (CHR) for Psychosis · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03428555 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre for Addiction and Mental Health
- Last refreshed: 9 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03428555.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing